Cipla USA Inc., a unit of Cipla Limited (500087), on Thursday said it has received approval from the U.S. Food and Drug Administration for its Albuterol Sulfate Inhalation Aerosol, a generic version of Ventolin HFA marketed by GlaxoSmithKline.
The product is the first AB-rated therapeutic equivalent of Ventolin HFA and is used to treat or prevent bronchospasm in adults and children aged four years and older, including exercise-induced bronchospasm.
According to IQVIA, the total U.S. albuterol market is valued at about $1.5 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.